Floatz logo

Vinorelbine

Neuroendocrine Neoplasm

Vanderbilt-Ingram Cancer CenterPhase 2Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Neuroendocrine Neoplasm cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
National Cancer Institute (NCI)
Phase 4BBB
ETOPOSIDE
National Cancer Institute (NCI)
Phase 2BB
Epirubicin
University of Michigan Rogel Cancer Center
Phase 2B
Octreotide Pamoate
National Cancer Institute (NCI)
Phase 3B
INTERFERON ALFA-2B
National Cancer Institute (NCI)
Phase 3B

View all 11 →

Same molecule, other indications

Vinorelbine is also rated in:

HER2 positive breast carcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
Recurrent Breast CarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
Hodgkins lymphomaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →